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Abstract
Clonal erythroleukemia developing in susceptible mice infected by Friend virus complex are associated with highly
recurrent proviral insertions at one of three loci called Spi-1, Fli-1 or Fli-3, leading to deregulated expression of oncogenic
Spi-1 or Fli-1 transcription factors or miR-17-92 miRNA cluster, respectively. Deregulated expression of each of these three
oncogenes has been independently shown to contribute to cell proliferation of erythroleukemic clones. Previous studies
showed a close relationship between Spi-1 and Fli-1, which belong to the same ETS family, Spi-1 activating fli-1 gene, and
both Spi-1 and Fli-1 activating multiple common target genes involved in ribosome biogenesis. In this study, we
demonstrated that Spi-1 and Fli-1 are also involved in direct miR-17-92 transcriptional activation through their binding to a
conserved ETS binding site in its promoter. Moreover, we demonstrated that physiological re-expression of exogenous miR-
17 and miR-20a are able to partially rescue the proliferation loss induced by Fli-1 knock-down and identified HBP1 as a
target of these miRNA in erythroleukemic cells. These results establish that three of the most recurrently activated
oncogenes in Friend erythroleukemia are actually involved in a same oncogenic network controlling cell proliferation. The
putative contribution of a similar ETS-miR-17-92 network module in other normal or pathological proliferative contexts is
discussed.
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Introduction
Despite the high number and heterogeneity of mutations
observed between tumors, a few recurrent oncogenic networks
usually drive proliferation and survival of most individual tumors
derived from a given cell type. It has recently been shown that in a
given tumor, driver mutations mostly impact only one gene in
each oncogenic network and that looking for mutually exclusive
mutations actually allows the identification of these networks [1].
Identifying and understanding such new oncogenic networks
remains an interesting challenge that should help the rational
design of new therapies.
Murine erythroleukemia induced by Friend viruses provides an
interesting model of oncogenesis driven by random proviral
integrations and allow the exploration of such oncogenic networks
[2,3]. Indeed, most of these clonal erythroleukemia are associated
with one of three recurrent proviral insertions leading to spi-1, fli-1
[4] [4] or fli-3 genes [5] deregulated expression.
Spi-1 and fli-1 encode two different transcription factors, Spi-1/
PU.1 and Fli-1, which belong to the same ETS family. The ETS
family comprises more than 30 members characterized by a
conserved DNA binding domain allowing their binding to a
common minimal GGAA motif [6]. Several studies already
established that Spi-1 or Fli-1 over-expression actively contributes
to the proliferation, survival and inhibition of differentiation of
Friend erythroleukemic cells [7–11]. Among many specific
mechanisms identified, Spi-1 and Fli-1 contribute to the inhibition
of erythroid differentiation by functional antagonisms against
GATA-1 [12] or EKLF [13], respectively. Fli-1 is a direct activator
of the bcl2 and mdm2 genes [14,15] and a repressor of ship1 [16],
whereas Spi-1 is a direct activator of the cyclin-dependent kinase
cdk6 [17]. We also showed that Spi-1 directly activates fli-1
expression in all erythroleukemic cells harboring an activated spi-1
locus [7]. Given the recurrent activation of these two factors
belonging to the same ETS family, we worked on the hypothesis
that they might contribute to erythroleukemia through the
deregulation of common target genes. In agreement with this
possibility, we recently established that both Spi-1 and Fli-1, like
many other ETS members, share several direct common target
genes including a large proportion of genes involved in ribosome
biogenesis [18].
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fli-3 encodes the well known oncogenic miRNA cluster miR-17-
92. This miR-17-92 cluster comprises six miRNAs that can be
grouped into four sub-families based on their seed sequence (miR-
17 and miR-20a, miR-18a, miR-19a and b and miR-92a) [19].
Following the first observation of frequent miR-17-92 over-
expression in B-cell lymphomas [20], it has been experimentally
demonstrated that its over-expression can indeed accelerate
development of B-cell lymphoma initiated by Myc deregulation
[21,22]. Since then, miR-17-92 deregulation has been document-
ed in many different cancers and its functional implication in
stimulation of cell proliferation and survival has been demonstrat-
ed in many different cell contexts [23–26] including in the factor-
dependent Friend erythroleukemic cell line HB60 harboring an
activated spi-1 locus [5]. Except for miR-18, the oncogenic
contributions of miR-17/20a, miR-19a/b and miR-92 have all
been demonstrated and several functional targets identified,
including E2F1, PTEN and BIM1 [26]. Intriguingly however,
miR-17/20a have also been reported to behave as an anti-
oncogene [27–29] but the cell context differences that determine
their oncogenic versus anti-oncogenic properties remain poorly
understood.
The present study aimed to investigate whether miR-17-92
could be a functional and direct target of Spi-1 and Fli-1 in Friend
erythroleukemia. We found that miR-17-92 is indeed expressed in
two erythroleukemic cell lines harboring either a spi-1 or fli-1
activated locus and that its expression decreases following Spi-1
and/or Fli-1 knock-down. We found in vitro that full miR-17-92
promoter activity is dependent on a conserved ETS binding site
and that Spi-1 and Fli-1 bind this promoter in vivo. We further
demonstrated that loss of proliferation induced by Fli-1 knock-
down can be at least partially rescued by exogenous whole miR-
17-92 cluster re-expression or by miR-17 and miR-20a only re-
expression. Altogether, these results indicate that the three most
frequently activated oncogenes in Friend erythroleukemia are
linked into a single oncogenic network contributing to cell
proliferation.
Materials and Methods
Cell lines, culture, and transfection
Mouse erythroleukemic cell line 745A (kindly provided by Dr F
Moreau-Gachelin, Curie Institute, France), has been originally
established from mice infected by Friend virus complex (composed
of defective SFFV and helper F-MuLV viruses) [30,31]. 745A cells
harbor SFFV proviral insertion at spi-1 locus responsible for
deregulated production of Spi-1/PU.1 transcription factor leading
in turn to fli-1 gene activation and deregulated production of Fli-1
transcription factor [7]. Mouse erythroleukemic cell line NN10
(kindly provided by Dr F Wendling, Gustave Roussy Institute,
France) has been established from newborn mice infected by
helper F-MuLV virus only [32]. NN10 cells harbor F-MuLV
proviral insertion at fli-1 locus responsible for deregulated
production of Fli-1. Clone#44 and NN10#5 has been derived
from parental 745A and NN10 cells respectively through the
establishment of Dox-inducible shRNA expression allowing
conditional Fli-1 knock-down as previously described [18]. Clones
NN10#17-92a and #17-92b expressing inducible exogenous
miR-17-92 and clone NN10#17-20 expressing inducible exoge-
nous miR-17 and miR-20a were derived from NN10#5 cells after
transfection with expression vector pcDNA4/TO (Invitrogen,
Cergy Pontoise, France) carrying the corresponding miRNA
coding regions followed by zeocin selection. All cell clones were
cultured at 37uC under 5% CO2 in a humidified incubator and in
Iscove’s modified Dulbecco’s medium (PAA Laboratories, Les
Mureaux, France) supplemented with 10% fetal calf serum (PAA
Laboratories) and antibiotics. Exogenous miRNA and/or Fli-1
shRNA productions were induced by adding 100 ng/ml of
Doxycycline (Dox) (Clontech, Saint-Germain-en-Laye, France).
Terminal erythroid differentiation of 745A#44 cells associated
with Spi-1 extinction was induced in the presence of 5 mM
HMBA (hexamethylene bisacetamide, Sigma, Saint-Quentin
Fallavier, France). Transfections were performed either by
lipofection using FuGENE 6 (Roche, Meylan, France) or by
nucleofection using the ‘‘cell line nucleofector Kit V’’ and program
G-16 on a Nucleofector electroporation device (Lonza, Basel,
Switzerland). Anti-miRs were purchased from Applied Biosystems.
20 pmol of anti-miRs were introduced into 2.105 cells using a
Nucleofector device and a ‘‘Cell line nucleofector kit V’’ using
program G-16 (Lonza, Basel, Switzerland). siRNAs transfections
were performed using the same protocol using 120 pmol of
siRNAs and 2.105 cells.
Plasmid constructs
pcDNA4/17-92 and pcDNA4/17-20 were obtained by cloning
PCR-amplified genomic DNA corresponding to the whole mouse
miR-17-92 cluster or to the miR-17 and miR-20a coding segments
downstream to the Dox-inducible CMV promoter in pcDNA4/
TO plasmid (Invitrogen, Cergy Pontoise, France). pGL3-EBS
reporter construct was obtained by cloning the mouse 2645/+15
miR-17-92 cluster promoter region upstream to the luciferase
coding region in pGL3basic (Promega, Charbonnie`res, France).
To mutate the 278 EBS from CGGAAG to ACGCGT in pGL3-
EBSmut, we first PCR amplified from pGL3-EBS the DNA
sequence immediately upstream of the 278 EBS with (2645/+15
promoter F) and (278 EBS mutagenesis UE) primers. We
similarly amplified the sequence downstream of the 278 EBS
with (2645/+15 promoter R) and (278 EBS mutagenesis DE)
primers. Both PCR products were digested by Mlu1 and Xho1
and ligated in the Xho1 site of the pGL3basic vector. Sequences of
primers used for these plasmid constructions are given in Table
S1.
Western blot analyses
Western blot analyses were performed on total cell lysates as
previously described [18] using the following antibodies: anti-Fli-1
(C-19) (sc-356; Santa Cruz), anti-actin (MAB1501; Millipore), anti
Spi-1 (T-21) (sc-352; Santa Cruz), anti-E2F1 (C-20) (sc-193; Santa
Cruz), anti-p21 (C-19) (sc-397; Santa Cruz), anti-TxNip (K0205-3;
MBL), anti PTEN (#9559; Cell Signaling), anti-cMyc (9E10) (sc-
40; Santa Cruz) and anti-Hbp1 (#83402; Abcam).
Gene set enrichment analyses
Microarray data from 745#44 cells untreated or treated for two
days in the presence of Dox alone, HMBA alone or both Dox and
HMBA have been previously obtained [18]. Lists of predicted
miRNA targets were established from the miRWalk database
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) by
compiling all mouse transcripts with 39UTR harboring putative
target sequences predicted by the three different algorithms
miRanda, miRDB and miRWalk with a p value,0.05. Predicted
targets lists were then used to perform gene set enrichment
analyses (GSEA) by comparing the transcriptome of untreated or
Dox+HMBA treated 745#44 cells (displaying the strongest
differential in pri-miR-17-92 levels) using the GSEA software
v2.0 (http://www.broadinstitute.org/gsea/index.jsp/) [33]. For
each miRNA target lists displaying significant differential expres-
sion in response to HMBA and Dox, we retrospectively compared
the mean relative expression levels of the corresponding leading
Spi-1 and Fli-1 Activate Fli-3
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edge subset of these lists between all four conditions (untreated,
Dox alone, HMBA alone or Dox and HMBA). Given the very
high similarity between miR-17 and miR-20a or miR-19a and
miR-19b, this retrospective analysis was performed on the
intersection of the leading edge subset of miR-17 and miR-20a
or miR-19a and miR-19b, respectively. File containing all gene
lists generated (excel file named ‘‘Genes lists GSEA’’) as well as
files containing transcriptome data used to perform GSEA
(manip745.grp, manip745.chip and manip745.gct) are provided
as supplementary data (Data S1 and S2).
mRNA and miRNA quantification
For mRNA quantification, total RNA was extracted using the
Rneasy PLUS minikit (Qiagen, Courtaboeuf, France) and reverse
transcribed using a Quantitect reverse transcription kit (Qiagen)
followed by quantitative PCR using a QuantiTect SYBR green
PCR kit (Qiagen) and specific primers indicated in Table S1.
mRNA specific signals were normalized to that of beta-actin
mRNA. For miRNA quantification, total RNA was extracted
using TriReagent (Sigma-Aldrich, Lyon, France) and reverse
transcribed using a TaqMan reverse transcription kit (Applied
Biosystems) followed by quantitative PCR performed using a
TaqMan qPCR assay (miR-17, miR-20a, miR-18, miR-19a, miR-
19b, miR-92a and U6 snoRNA specific kits: Applied Biosystems).
miRNA specific signals were normalized using U6 RNA level.
Chromatin immunoprecipitation assays (ChIP)
ChiP assays were performed exactly as previously described [18]
using anti-Spi-1 (sc-352; Santa Cruz), anti-Fli-1 (sc-356; Santa-
Cruz) and anti-UBC9 (sc-10759; Santa Cruz) followed by real-
time PCR using a SYBR green PCR kit and specific primers
indicated in Table S1.
Promoter assays
NN10#5 cells (26105) were co-transfected using Fugene6
(Roche, Meylan, France) with a fixed amount of a b-galactosidase
expressing vector and constant molar amounts of pGL3, pGL3-
ETS or pGL3-EBSmut luciferase reporters plasmids while keeping
the total amount of transfected DNA constant to 5 mg. After
24 hours, cells lysates were assayed for luciferase and b-
galactosidase activities by chemiluminescence using the luciferase
high sensitivity reporter gene assay and the b-galactosidase
reporter gene assay kits (Roche, Meylan, France). Luciferase
activities were normalized to b-galactosidase activities.
Results
Spi-1 and Fli-1 directly activate miR-17-92 expression in
745A#44 cells
We previously established that Spi-1 and Fli-1, the two most
frequently activated oncogenes in Friend erythroleukemia, display
tight functional connections since Spi-1 directly activates the fli-1
gene [7] and they both directly activate target genes involved in
ribosome biogenesis [18]. These results prompted us to investigate
if Spi-1 and Fli-1 could also be involved in the direct activation of
fli-3, the third most commonly activated locus in Friend
erythroleukemia, encoding the known miR-17-92 oncogenic
miRNA cluster [5]. For this purpose, we used our previously
described 745A#44 erythroleukemic cells model carrying an
activated Spi-1 locus and expressing Doxycyclin-inducible Fli-1
shRNA [18]. These cells can be induced to differentiate by the
additive effect of HMBA (hexamethylene bisacetamide) and
Doxycycline leading to Spi-1 extinction and shRNA mediated
Fli-1 knockdown, respectively (Figure 1B). We found that
successive decrease of Fli-1 by Dox (lane 2), Spi-1 by HMBA
(lane 3) or of both Spi-1 and Fli-1 by combined Dox and HMBA
treatments (lane 4) were associated with a progressive decrease in
pri-miR-17-92 transcripts as well as all six mature miRNAs of the
cluster (Figure 1A). Such a progressive decrease in pri-miR-17-92
transcript levels is compatible with the hypothesis of an additive
contribution of Spi-1 and Fli-1 in miR-17-92 cluster transcrip-
tional activation. Interestingly, we noticed a highly conserved ETS
binding site located at position 278 (Figure 2A and 2B) in the
known miR-17-92 promoter [21,34]. Using luciferase reporter
assays, we confirmed that the mouse 2645/+15 promoter region
indeed displayed a strong promoter activity that decreased by 40%
after the 278 ETS binding site mutation (Figure 2B). In
agreement with these results, ChIP assays performed on
745A#44 untreated cells showed an eight and three fold
enrichment of the miR-17-92 promoter region compared to
control GAPDH promoter region in chromatin immunoprecipi-
tated with Spi-1 or Fli-1 specific antibodies, respectively. In
contrast, chromatin immunoprecipitated with control UBC9
Figure 1. miR-17-92 expression correlates with ETS transcrip-
tion factors Spi-1 and Fli-1 decrease during 745A#44 cells
differentiation. A: As indicated, 745A#44 cells have been treated for
two days with or without Dox to induce Fli-1 knockdown and for two
other days in the same conditions with or without addition of 5 mM
HMBA to induce differentiation associated with Spi-1 extinction. Pri-
miRNA-17-92 transcript and mature miRNAs levels were then deter-
mined by semi-quantitative real-time RT-PCR using actin mRNA or U6
RNA as reference, respectively. The upper panel shows relative
transcripts levels following Dox and/or HMBA treatment normalized
to untreated cells levels (means and standard deviations from 3
independent experiments). Asterisks show significant differences
compared to the untreated condition (t-test, p,0,05). B: Typical results
of a Western blot analysis of Fli-1 and Spi-1 protein levels after
treatments used in A.
doi:10.1371/journal.pone.0046799.g001
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antibody showed no significant enrichment in miR-17-92
promoter (Figure 2C). These results altogether support the
hypothesis that both Spi-1 and Fli-1 contribute to miR-17-92
cluster expression through a direct binding to its promoter,
potentially at the functional and conserved ETS binding site we
identified.
Identification of miR-17/miR-20a and miR-19a/miR-19b
signatures in the transcriptome of 745A#44 cells
displaying decreased levels of miR-17-92 cluster
In order to test the functionality of individual miRNA of the
miR-17-92 cluster in 745A#44 cells, we checked if their
transcriptome was significantly affected by miR-17-92 expression
decrease induced by combined HMBA and Dox treatments. We
addressed this question using Gene Set Enrichment Analysis using
transcriptome data obtained from 745A#44 cells treated or not
for two days with HMBA and Dox [18] and lists of miRNA targets
predicted from 39UTR analyses by three different algorithms
(miRanda, miRDB and miRWalk) [35]. This analysis (Figure 3A)
revealed that genes belonging to the predicted targets lists of miR-
17, miR-20a, miR-19a and miR19b but not to those of miR-18a
or miR-92a were significantly over-represented among genes up-
regulated in response to HMBA and Dox (resulting in down
regulation of miR-17-92 cluster). As a control, target genes of miR-
451, which is up-regulated in response to HMBA [36], tend in
contrast to be over-represented among down-regulated genes. We
also compared mean expression levels of genes in the leading edge
subsets of common miR-17/miR-20a, common miR-19a/miR-
19b and miR-451 targets identified in response to HMBA in the
other two conditions (+Dox only or +HMBA only) which are
associated with intermediate pri-miR-17-92 expression levels
(Figure 1). As expected from authentic target genes, variations in
the levels of miR-17/miR-20a and of miR-19a/miR-19b targets
were inversely correlated with the variations of pri-miR-17-92a
levels (compare Figure 3B with pri-miR-17-92a and miRNAs
profiles in Figure 1A). In summary, these analyses indicated that
miR-17-92 cluster in 745A#44 cells is mainly involved in the
down-regulation of predicted targets of miR-17/miR-20a and
miR-19a/miR-19b rather than miR-18a or miR-92a.
Fli-1 directly activates miR-17-92 expression in NN10#5
cells
The above results prompted us to ask if miR-17-92 cluster
expression was also regulated by Fli-1 in erythroleukemic cells
harboring a fli-1 instead of spi-1 proviral integration. We used as a
model our previously described NN10#5 cells harboring an
activated fli-1 and a dox-inducible Fli-1 shRNA expression [18].
Dox treatment of NN10#5 led to a strong reduction of Fli-1 levels
associated with a 60% decrease of pri-miR-17-92 transcript level
and a 40% decrease of mature miR-17 and miR-20a levels
(Figure 4A). Dox treatment was also associated with smaller and
not statistically significant decreases of all other mature miRNAs.
We then showed by reporter gene assay that the mouse2645/+15
promoter region displayed a strong promoter activity in NN10#5
cells that decreased by 40% following mutation of the 278 ETS
binding site (Figure 4B). Moreover, ChiP assays confirmed Fli-1
recruitment on endogenous miR-17-92 promoter in NN10#5 cells
as revealed by a 3.5 higher enrichment of the corresponding
Figure 2. Spi-1 and Fli-1 directly activate miR-17-92 promoter
in 745A#44 cells. A: Schematic map of the mouse chromosome 14:
115,439,000–115,445,000 interval harboring the miR-17-92 cluster and
flanking regions. Blacks and white boxes drawn upper the scale (250 bp
units) correspond to the putative miR-17-92 primary transcript and to
the 2645/+15 promoter region used in B, respectively. Locations of the
6 different mature miRNAs sequences of the cluster are indicated by
grey boxes. Primers used for ChIP analyses of Spi-1 and Fli-1 binding are
indicated by black triangles. Sequences alignment illustrates 278 EBS
conservation in Human, Mouse, Opossum, Xenopus and Zebrafish
genomes. B: Reporter gene assays showing promoter activity of the
2645/+15 region and its partial dependency on the conserved 278
EBS. 745#44 cells were co-tranfected with pCMV-bGal and pGL3, pGL3-
EBS or pGL3-EBSmut luciferase reporter constructs as indicated.
Luciferase activities were normalized to b-galactosidase determined
24 h after transfection and normalized relative luciferase activities were
expressed with respect to the wild type construct (means and standard
deviations from 3 different experiments). C: Chromatin immunoprecip-
itation (ChIP) assays showing Spi-1 and Fli-1 binding on the
endogenous miR-17-92 promoter in 745A#44 cells. ChiPs assays were
performed using Spi-1, Fli-1 or UBC9 (negative control) antibodies
followed by q-PCR of mir-17-92 promoter and three negative control
regions: GAPDH promoter, 129k and 153k. Results are expressed as
relative enrichments of the sequence of interest over the GAPDH
promoter sequence normalized to the enrichment determined on 129k
region with control UBC9 antibody (means and standard deviations
from 3 independent experiments). Asterisks indicate significant increase
in the enrichment of miR-17-92 compared to 153k control sequences
obtained with Fli-1 and PU.1 antiobodies (p,0.05).
doi:10.1371/journal.pone.0046799.g002
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region over GAPDH control region in chromatin immunoprecip-
itated by Fli-1 antibody but not by control UBC9 antibody
(Figure 4C). These results indicate that a contribution to the direct
transcriptional activation of the miR-17-92 cluster by constitu-
tively expressed ETS factors seems to be a common property of
Friend erythroleukemic cells harboring either spi-1 or fli-1 proviral
integrations.
miR-17-92 functional implication in NN10#5 cells
proliferation control downstream of fli-1
We previously established that Dox-induced Fli-1 knock down
strongly decreased NN10#5 cells proliferation [18]. The above
results raised the interesting possibility that Fli-1 critical contribu-
tion to cell proliferation could be mediated at least partly by the
miR-17-92 cluster. To address this question, we first tried to
maintain miR-17-92 expression in absence of Fli-1 in order to test
if NN10#5 cells proliferation could be rescued during Dox
treatment. For that purpose, we derived sub-clones from parental
NN10#5 cells with a stable integration of a plasmid carrying the
whole miR-17-92 cluster under the control of a Dox-inducible
promoter. We thus identified clones #17-92a and #17-92b that
maintained stable levels of mature miR-17 and miR-20a in the
presence or absence of Dox (Figure 5A) while still displaying Dox-
inducible Fli-1 knock down (Figure 5B). As previously reported
[18] Dox treatment of parental NN0#5 cells abolishes their
proliferation. In contrast, Dox treatment of#17-92a and#17-92b
cells induced an only 2 fold decrease in proliferation rates
(doubling time of 12 hours for NN10#5 and #17-92 clones
without Dox versus 24 hours for #17-92a and #17-92b cells in
presence of Dox) thus indicating a partial compensation of Fli-1
loss (Figure 6A). We also derived following the same strategy a
single clone from 745#44 cells that maintains stable levels of pri-
miR-17-92 and miR-20a after Fli-1 knockdown (Figure S1).
However, unlike in NN10#5, restoration of pri-miR-17-92 and
miR-20a levels in 745#44 cells did not rescue cell proliferation
decrease induced by Fli-1 loss thus suggesting different parallel
contributions of Fli-1 between the two cell lines. We then wanted
to know which members of the miR-17-92 cluster were involved in
NN10#5 cells proliferation. We decided to focus first on miR-17
and miR-20a which are the most significantly downregulated
miRNA of the cluster after Dox treatment. In addition, miR-17
Figure 3. Up-regulation of miR-17-20a and 19a-19b predicted targets following Spi-1 and Fli-1 knockdown in 745A#44 cells. A:
GSEA (Gene Set Enrichment Analysis) of predicted miRNA targets in 745A#44 cells treated for two days with both HMBA and Dox versus untreated
cells. Lists of targets predicted by three different algorithms (miRanda, miRDB and miRWalk) were compiled for each miRNAs from miRWalk web site.
The size column displays the total number of predicted targets used for the analysis, ES and NES indicate the standard and normalized enrichment
scores respectively and the last two columns display the normalized p-values and false discovery q-values of the enrichments. Significant enrichments
are indicated in bold. B: Mean relative expression profiles of the leading edge subsets of common predicted targets for miR-17/20a, miR-19a/19b and
miR-451 identified by GSEA in response to progressive decrease of miR-17-92 expression or progressive increase of miR-451 induced by indicated
combinations of HMBA and Dox treatment in 745A#44 cells.
doi:10.1371/journal.pone.0046799.g003
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and miR-20a are two closely related miRNA which share a
common seed sequence and have several well described targets.
Using the same approach, we derived#17-20a cells allowing Dox-
inducible expression of miR-17 and miR-20a only instead of the
whole miR-17-92 cluster. Like in #17-92a and #17-92b, miR-17
and miR-20a levels remained roughly unaffected by Dox
treatment in #17-20 cells (Figure 5A) while Fli-1 remained
strongly down regulated (Figure 5B). Interestingly, when com-
pared to parental NN10#5 cells,#17-20a cells displayed the same
proliferation rescue in Dox as did #17-92 a and #17-92b cells
(Figure 6A), thus indicating that combined miR-17 and miR-20a
re-expression is sufficient to reproduce the effect of the whole miR-
17-92 cluster. In a complementary approach, we repeated these
proliferation measures between parental #5 and #17-92a cells
with concomitant transfection of a miR-17 and miR-20a anti-
miRs mixture, of miR-92 anti-miR or of control anti-miR. We
used a miR-17 and miR-20a anti-miRs mixture since both
miRNA share a common seed sequence and have essentially
identical targets. Transfection of either miR-92 or control anti-
miRs did not affect the partial proliferation rescue in #17-92 cells
in presence of Dox (Figure 6B). In contrast, miR-17 and miR-20a
anti-miRs transfection completely suppressed the proliferation
rescue of #17-92a cells in the presence of Dox, thus confirming
that exogenous miR-17-92 cluster contribution is strictly depen-
dent on miR-17 and miR-20a function.
Figure 4. Fli-1 directly activates miR-17-92 promoter and
contributes to miR-17 and miR-20a expression in NN10#5
cells. A: NN10#5 cells have been cultured for two days in absence or
presence of Dox used to induce Fli-1 knock-down before analysis.
Histogram shows the relative decreases of pri-miRNA-17-92 transcript
and mature miRNA levels in treated versus untreated cells (means and
standard deviations from 3 independent experiments) with significant
(p,0.01) decreases indicated by asteriks. A western blot analysis
confirming the strong decrease of Fli-1 protein in treated cells is shown
under the histogram. B: Reporter gene assay showing promoter activity
of the 2645/+15 region and its partial dependency on the conserved
278 EBS. NN10#5 cells were co-transfected as indicated for 745#44
cells in Figure 2B. C: ChIP analyses performed in NN10#5 cells using Fli-
1 or control UBC9 antibodies followed by q-PCR of miR-17-92 promoter
and GAPDH or 129k negative control regions. Results are expressed as
relative enrichments normalized to background enrichment determined
on the GAPDH region (results from a single experiment).
doi:10.1371/journal.pone.0046799.g004
Figure 5. Restoration of initial levels of miR-17 and miR-20a
following Dox-induced Fli-1 knockdown in NN10#5 cells. #17-
92a, #17-92b or #17-20 cell clones have been derived from parental
NN10#5 cells following stable transfection of a Dox-inducible
expression cassettes of the whole miR-17-92 cluster or only miR-17-
20a sub-cluster, respectively. A: Parental NN10#5 cells and their
derivative clones #17-92a, #17-92b or #17-20 harboring inducible
exogenous whole miR-17-92 miRNA cluster or miR-17-20a sub-cluster
were cultured for two days in the presence or absence of Dox and the
relative levels of pri-miR-17-92, miR-17 and miR-20a levels were
determined by qRT-PCR as in Figure 4. Results are expressed as
+Dox/-Dox ratios (means and standard deviations from 3 independent
experiments). B: Fli-1 expression analysis by western blot in indicated
cell clones after two days in presence or absence of Dox using b-actin
signal as a loading control.
doi:10.1371/journal.pone.0046799.g005
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Identification of HBP1 as a miR-17/miR-20a target in
NN10#5 and 745A#44 cells
Having established miR-17 and miR-20a functionality in
NN10#5 cells proliferation downstream of Fli-1, we tried to
identify miR-17/20a targets able to explain this effect. Surpris-
ingly, Western blots analyses revealed that none of several miR-
17/miR-20a targets already identified in other cell contexts
(including p21, PTEN, E2F1 or TXNIP) displayed the expected
increased level in response to Dox treatment (Figure 7A). We then
looked for other possible candidates in the transcriptome analysis
presented in Figure 3. We noticed that HBP1, which has been
identified as a miR-17 target in human breast cancer cells [37] was
included in the leading edge genes subset whose expression
increases in response to HMBA in 745A#44 cells. Interestingly,
HBP1 mRNA levels also increased in response to Dox in NN10#5
cells and importantly this increase was strongly attenuated in #17-
92a or #17-20a cells (Figure 7B). Western blots analyses showed
that HBP1 protein levels strongly increased in response to Dox in
NN10#5 cells but not in the #17-92a, #17-92b or #17-20a
clones (Figure 7C). Moreover, the .7 fold HBP1 protein level
increase in Dox-treated parental NN10#5 cells was much higher
than the 2 fold mRNA level increase (Figure 7D), as expected from
the known miRNA mechanism of action at the translation level.
Similarly, we found no variation of TXNIP or PTEN protein
levels in 745A#44 cells in response to HMBA or Dox treatment
(Figure 7E). In contrast, both HBP1 transcript (Figure 7F) and
HBP1 protein (Figure 7G, H) levels were strongly increased in
response to HMBA while HBP1 protein levels but not HBP1
mRNA were further markedly increased in response to Dox thus
indicating a post-transcriptional regulation. From these results, we
conclude that HBP1 can be considered as an authentic miR-17
and miR-20a target in both NN10#5 and 745A#44 cells. These
results prompted us to try to restore the proliferation of NN10#5
cells in the presence of Dox using Hbp1 siRNA transfection.
Unfortunately, despite successful knockdown of Hbp1 mRNA and
slight but significant increase of cell proliferation, Hbp1 siRNA
Figure 6. miR-17 and miR-20a are sufficient for partial rescue of Fli-1 knock-down induced cell proliferation arrest. A: Equal numbers
of parental NN10#5 cells and of their three derivative clones #17-92a, #17-92b and #17-20 were cultured for 96 h in the presence or absence of
Dox as indicated. Histogram shows cell concentrations (log scale) at 48 h, 72 h and 96 h time points, 48 h being the minimum Dox treatment time
required for complete Fli-1 knockdown (mean and standard deviations from 3 independent experiments). Asterisks (p,0.05) and double asterisks
(p,0.01) show significant differences between NN10#5 cells and derivatives in presence of Dox. B: Equal numbers of NN10#5 or #17-92a cells were
transfected with control, anti-miR-92a or a mixture of anti-miR-17 and anti-miR-20a and cultured in the presence or absence of Dox. Cell proliferation
was determined 72 h after transfection, the latest time point at which anti-miRs are still efficient. Mean and standard deviations of cell densities
(n = 3) are shown (linear scale). Statistically significant differences are indicated by asterisks (p,0.01).
doi:10.1371/journal.pone.0046799.g006
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transfection was not associated with concomitant decrease of
Hbp1 protein level thus alleviating definitive conclusion concern-
ing the real contribution of Hbp1 downstream of Fli-1 and Fli-3
(Figure S2).
Discussion
Friend erythroleukemia develops in susceptible mice infected by
the two virus of the Friend viral complex: SFFV and F-MuLV.
Although proviral insertions are supposed to randomly occur into
infected cells genome, clonal erythroleukemia only develops from
erythroid progenitors harboring proviral insertion at one of a very
few loci, often leading to neighboring genes constitutive activation.
More than 75% of these SFFV or F-MuLV recurrent proviral
insertions occur upstream of spi-1 or fli-1 genes, respectively, and
lead to the constitutive expression of the ETS family transcription
factors Spi-1 and Fli-1, which play a major role in blocking
differentiation and promoting proliferation and cell survival. Such
Figure 7. miR-17 and miR-20a contribute to Hbp1 regulation in NN10#5 and 7451#44 cells. A, B, C and D : Parental NN10#5 cells and
their derivative #17-92a, #17-92b and #17-20 were cultured for two days in the presence or absence of Dox before Western blot and qRT-PCR
analyses of known targets of miR-17-92 cluster. A: Western blot analysis of non-regulated targets in NN10#5 cells. B: Histograms show relative levels
of hbp1 mRNA in the indicated Dox-treated cells normalized to that in untreated cells (means and standard deviations from 3 experiments). Asterisks
indicate significant differences induced by Dox treatment (p,0.05). C: Western blot analysis of Hbp1 protein. D: Quantification of Hbp1 protein level
variations in response to Dox between the indicated cells (+Dox/-Dox ratios of Hbp1 signal standardized to Actin signal determined by densitometric
analysis of Western blot shown in C). E, F, G and H : 745#44 cells were grown as in Figure 1 for two days in the presence or absence of HMBA or Dox
as indicated. E: Western blot analysis of non-regulated targets. F: Histograms show relative levels of hbp1 mRNA (typical results from two different
experiments). G: Western blot analysis of Hbp1 protein (typical results from two different experiments). H: Quantification of relative levels of Hbp1
protein standardized to actin.
doi:10.1371/journal.pone.0046799.g007
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highly recurrent activation of one of these two transcription factors
belonging to the same ETS family led us to hypothesize that Spi-1
and Fli-1 could contribute to erythroleukemia through common
target genes deregulation. In strong support to this hypothesis, we
recently established that Spi-1 and Fli-1 indeed directly activate
many common target genes involved in ribosome biogenesis [18]
and do contribute to high ribosomes content in Friend erythro-
leukemic cells (data not shown). Going one step further, we
showed here that Spi-1 and Fli-1 are also direct activators of the
miR-17-92 miRNA cluster, previously identified as the third most
frequently activated oncogenic locus by F-MuLV proviral
insertions. Moreover, we showed that restoration to their initial
levels of only two members of this cluster, miR-17 and miR-20a, is
sufficient to partially rescue the loss of proliferation induced by Fli-
1 knock-down in erythroleukemic cells harboring activated fli-1
locus. Altogether, this study allows us to conclude that three of the
most recurrently activated oncogenes in Friend erythroleukemia
contribute to a same oncogenic network required to promote
erythroleukemic cells proliferation.
Our experimental results support a direct activation of miR-17-
92 cluster by Spi-1 and Fli-1 based on the strong correlation
between pri-miR-17-92 and Spi-1 and/or Fli-1 levels, on the
dependency of 40% of miR-17-92 promoter activity on the
integrity of a conserved ETS binding site and on the in vivo
recruitment of Spi-1 and/or Fli-1 on the corresponding region in
both 745#44 and NN10#5 erythroleukemic cells. Knowing that
Myc is a major positive regulator of miR-17-92, we also excluded
its contribution downstream of Spi-1 and Fli-1 by verifying that
Myc protein levels were not affected by Spi-1 and/or Fli-1
knockdown in 745#44 or by Fli-1 knockdown in NN10#5 cells
(Figure S3). In contrast to the present results obtained in
erythroleukemic cells, another recent study showed that Spi-1/
PU.1 increase involved in macrophage differentiation contributes
to miR-17-92 down-regulation without PU.1 binding on its
promoter but through the direct activation of egr2 gene encoding
a transcriptional repressor of miR-17-92 promoter activity [38].
These different results suggest that miR-17-92 regulation by Spi-
1/PU.1 is strongly cell context dependent.
Our experimental results support the functional implication of
miR-17 and miR-20a in erythroleukemic cells proliferation
downstream of Fli-1 based on the rescue of proliferation loss
induced by Fli-1 knock down following the restoration of these two
miRNA to their initial levels. Moreover, transfection of miR-17
and miR-20a anti-miRs confirmed that this rescue is not due to
clone effect and further supports our conclusion. This conclusion is
in apparent contradiction to the recent demonstration of the anti-
proliferative effect of miR-17 in normal erythroid progenitors by
Li et al [29]. However, interesting comparison between the two
studies may help to understand the basis of these opposite effects of
miR-17 on cell proliferation. First, Li et al. achieved robust miR-
17 overexpression by retroviral transduction. Since it seems
reasonable to think that miR-17 effect could be dose-dependent, it
would be interesting to compare miR-17 levels between NN10#5
cells and cell lines overexpressing it from Li et al. study. We
noticed that miR-17 levels in NN10#5 cells are notably low
compared to K16 erythroleukemic cells harboring a fli-3
rearrangement [5] (Figure S4). One possibility could be that
miR-17 levels in NN10#5 cells are insufficient to reduce
proliferation as it is observed following strong overexpression in
erythroid progenitors [29]. We also noticed that the antiprolifer-
ative effect of miR-17 was associated with increased levels of P53,
thus suggesting [29] that P53 might be functionally involved. The
absence of functional P53 in NN10 (F Moreau-Gachelin, personal
communication) and 745A cell lines [39] might therefore be
another cause of the lack of antiproliferative effect of miR-17 in
these cell lines. In that context, the identification of Hbp1 as a
miR-17 target in NN10#5 and 745#44 cells is interesting.
Indeed, in addition to being a negative regulator of the Wnt
signaling pathway [40] or of MIF [41], Hbp1 is known to interact
with Myc and to inhibit its transcriptional activity [42]. Moreover,
Myc itself is a well known oncogene that stimulates proliferation
but can also induce P53-dependent proliferation arrest due to its
capacity to activate the ARF-MDM2-P53 oncogenic stress
pathway when expressed at high levels [43]. Altogether these
data lead us to propose a working model where the duality of miR-
17 effect on cell proliferation could be explained by its dose-
dependent and Hbp1-mediated regulation of Myc activity and its
strong dependence on the p53 status of the cells (see diagram in
Figure S5).
During this study, we found that several other known miR-17-
92 targets such as PTEN (miR-19 and miR-17/20a target) [24],
TxNIP/VDUP (miR-17/20a target) [44] E2F1 (miR-17/20a)
[45,46] and P21 (miR-17/20a target) [45,47] were surprisingly not
regulated in response to miR-17-92 expression variations in
NN10#5 and 745A#44 cells. These results highlight the
increasingly recognized cellular context dependency of miRNA
activity. For example, several RNA-binding proteins have been
recently shown to control the accessibility and regulation of a given
mRNA by a specific miRNA such as PUM2 that is involved in p27
mRNA regulation by miR-221 and miR-222 [48] or RPL11
involved in the control of Myc mRNA regulation by miR-24 [49].
Furthermore, target mRNA regulation by a given miRNA is
dependent on the total amount of all other mRNA expressed in
the same cell that are able to bind this given miRNA and thus to
act as competitors [50]. The identification of such missing putative
RNA binding proteins and/or excess of mRNA competitors
responsible for the lack of regulation of several known miR-17-92
targets in NN10 erythroleukemic cells remains an interesting
challenge for future studies.
Interestingly, deregulation of ETS transcription factors and
miR-17-92 was independently described in multiple other
proliferative contexts. For example, Fli-1 levels are known to be
involved in the proliferation control of activated splenic B
lymphocytes [51] whereas deregulated miR-17-92 has been
independently involved in lymphoid hyperproliferative diseases
[20]. Furthermore, it was shown that B-lymphocytes from human
lupus patients [52] or from lupus erythematous mouse model
MRL/lrp displayed increased Fli-1 expression [53] whereas
another study showed an up-regulated miR-17-92 expression in
mouse models of lupus [54]. It is therefore very tempting to
speculate that the Fli-1/miR-17-92 cascade identified here in
mouse erythroleukemic cells could also be involved in stimulation
of normal and pathological B cell proliferation. Similarly, Fli-1 has
been shown to contribute to the high malignancy of the breast
cancer cell line MDA-MB231 [55] whereas another study
independently showed the inhibition of Hbp1 by miR-17 in the
same cells [37]. Moreover, miR-20a has been shown to targets
E2F1 and prevents apoptosis of the PC3 prostate cancer cell line
[46] whose tumorigenicity has been independently shown to be
dependent on Ets2 transcription factor [56] while another prostate
cell line is also characterized by Ets2 over expression and Hbp1
down regulation [41]. These other data further suggest that miR-
17-92 deregulation could be a generic property of several other
ETS factors contributing to their oncogenicity.
In conclusion, the present study demonstrated that the three
most frequently activated oncogenes in Friend erythroleukemia
are involved in a same oncogenic network including an ETS/
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miR-17-92 module that might be involved in other proliferative
contexts.
Supporting Information
Data S1 Microarray data. Microarray data from 745#44
cells untreated (2H2D) or treated for two days in the presence of
Dox alone (2H2D), HMBA alone (+H2D) or both Dox and
HMBA (+H+D) have been previously obtained (Juban et al, 2009,
Mol Cell Biol 29: 2852–64). These microarray data are included in
the following three files: Manip745.gct (normalized expression
data); Manip745.chip (microarray probe description); Man-
ip745.cls (class description). These three files are provided as a
single compressed file «microarray data.zip».
(ZIP)
Data S2 GSEA analyses. Lists of predicted miRNA targets
were established from the miRWalk database (http://www.umm.
uni-heidelberg.de/apps/zmf/mirwalk/) by compiling all mouse
transcripts with 39UTR harboring putative target sequences
predicted by the three different algorithms miRanda, miRDB
and miRWalk with a p value,0.05. Predicted target gene lists
were then used to perform gene set enrichment analyses using the
GSEA software v2.0 (http://www.broadinstitute.org/gsea/index.
jsp/) after uploading the above three microarray data files and
performing two successive comparisons (2H2D vs +H+D and
2H2D vs +H2D). Gene list results are given on separate sheets
for each miRNA in file Data S2 (‘‘Gene Lists GSEA.xlsx’’):
Column 1: predicted target gene list used for GSEA; Column 2:
subset list of predicted target genes present on microaarray;
Column 3: leading edge subset of genes that were found to be
either up or downregulated by comparing 2H2D vs +H+D
(normalized p value indicated on the top of the column); Column
4: leading edge subset gene list that were found to be either up or
downregulated by comparing 2H2D vs +H+D (normalized p
value indicated on the top of the column); Column 5: intersection
between leading edge gene lists in columns 3 and 4. Lists of leading
edge common targets for miR-17 and miR-20 (intersection of the
four gene lists in columns 3 and 4 on sheets miR-17 and miR-20),
miR-19a and miR19b (intersection of the four gene lists in
columns 3 and 4 on sheets miR-19a and miR-19b) as well as for
miR-451 (intersection of gene lists in columns 3 and 4 in sheet
miR-451) that have been used to generate the histograms
presented in Figure 3B, C and D are given in sheet named «Gene
list profile».
(XLSX)
Figure S1 Restoration of pri-miR-17-92 and miR-20a
levels in 745#44 cells does not rescue the decrease of
cell proliferation induced by Fli-1 loss. Clone 745#44G3
was derived from 745#44 cells following transfection with plasmid
pcDNA4/17-92 carrying the whole miR-17-92 cluster under the
control of a Dox-inducible promoter. Equal number of 745#44
and 745#44G3 cells were then seeded in the presence or absence
of Dox, numbered every next three days whereas both pri-miR-
17-92 and miR-20a levels were quantified at day 2 by qRT-PCR
as in Figure 1A. A: Results of qRT-PCR showing the rescue of
both pri-miR-17-92 and miR-20a levels in the presence of Dox in
745#44G3 cells. B: Results of cells numbering showing the same
decrease of proliferation induced by Dox treatment in both
745#44G3 and 745#44 cells.
(TIF)
Figure S2 Hbp1 siRNA transfection increases NN10#5
cells proliferation in the presence of Dox. Dox-treated
NN10#5 cells were transfected twice either with Hbp1 siRNA or
with control Luc siRNA 24 h and 48 h following the first addition
of Dox and then analyzed 24 h later. A: relative levels of Hbp1
mRNA (standardized to actin mRNA) determined by qRT-PCR
and showing expected decrease following Hbp1 siRNA transfec-
tion compared to control siRNA. B: Western blot analysis of Hbp1
and actin (loading control) proteins showing no detectable
decrease following Hbp1 siRNA transfection compared to control
siRNA. C: final cell concentration (mean and standard deviation
from 3 independent experiments) showing significant increase
induced by Hbp1 siRNA transfection compared to control Luc
siRNA. Note that the discrepancy between the expected decrease
of Hbp1 mRNA but the absence of corresponding decrease of
Hbp1 proteins levels might reflect complex post-transcriptional
and/or post-translational regulations but does not formally
exclude the occurrence of transient Hbp1 protein levels induced
by Hbp1 siRNA during the course of the experiment. However
due to this discrepancy no definitive conclusion could be drawn
concerning the real contribution of the increase of Hbp1 to
proliferation arrest induced in the presence of Dox.
(TIF)
Figure S3 Western-blot analysis of Myc proteins in
treated and untreated 745#44 and NN10#5 cells.
745#44 cells (A) were cultured for two days in the presence or
absence of HMBA and/or Dox as in Figure 1A and NN10#5 for
two days in the presence or absence of Dox as in Figure 3A before
Western blot analysis of Myc and actin (loading control) proteins.
The absence of detectable variation of Myc proteins levels
indicates that Myc does not contribute to the decrease of miR-
17-92 miRNA cluster expression observed in treated cells (see
Figure 1A and 3A).
(TIF)
Figure S4 Comparison of miR-17, miR18, miR-19a,
miR19b and miR92 levels between NN10#5, 745A#44
and K16 erythroleukemic cells. miRNA levels were deter-
mined by q-RT-PCR and standardized to that of U6 RNA (means
and standard deviations from 3 independent experiments). Note
that these quantifications are not absolute quantifications and only
allow confident comparisons for each given between the different
cells lines. Variations of the miRNA/U6 ratios between miRNAs
are only indicative of the real relative levels of the corresponding
miRNAs assuming a same efficiency for all PCR reactions.
Significant differences between cell lines are indicated by asterisks.
Table shown under the histogram indicate Student tests p-values
obtained in two by two comparisons performed between cell lines
for each miRNA.
(TIF)
Figure S5 Diagram summarizing the inter-relation-
ships established in our study and illustrating the pro-
proliferative (A) or anti-proliferative (B) alternative
contribution of miR-17-20a. Previously known and newly
established relationships are indicated in black and red respec-
tively. Myc has already been shown to either stimulate
proliferation (oncogenic pathway 1) when expressed at low levels
or to induce proliferation arrest through the ARF-MDM2-P53
pathway (oncogenic stress pathway 2) when expressed at high
levels. HBP1 itself has already been shown to interact and to
inhibit Myc activity. Due to this property of HBP1, our finding
that miR17 and miR20a downregulate HBP1 strongly suggests
that these two miRNA contribute to increase Myc activity. In fully
transformed cells with no functional P53 such as established
erythroleukemic cells lines (A) increased Myc activity induced by
deregulated expression of miR17 and miR20a cannot induce
oncogenic stress thus explaining their pro-proliferative effect. In
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contrast, in cells harboring functional P53 such as normal
erythroid progenitors (B), increased Myc activity mediated by
deregulated expression of miR17 and miR20a induces oncogenic
stress thus explaining their anti-proliferative effect. Please note that
independently of the Spi-1-.Fli-1.Fli-3 regulatory cascade, Spi-
1, Fli-1 and Fli-3 activations obviously each display parallel and
specific contributions that, for clarity, are not presented on this
simplified diagram. The existence of these parallel contributions is
clearly indicated by our finding that complete restoration of Fli-3
levels only partially rescues proliferation loss following Fli-1
knockdown in NN10#5 cells (see Figure 6A) and does not rescue
proliferation loss following Fli-1 knockdown in 745#44 cells (see
Figure S1).
(TIF)
Table S1 Oligonucleotides used in this study.
(DOCX)
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